Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography
- 5 February 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 70 (4), 842-853
- https://doi.org/10.2337/db20-1096
Abstract
Targeting of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is an emerging strategy in antidiabetic drug development. The aim of this study was to develop a positron emission tomography (PET) radioligand for the GIPR to enable the assessment of target distribution and drug target engagement in vivo. The GIPR-selective peptide S02-GIP was radiolabeled with 68Ga. The resulting PET tracer [68Ga]S02-GIP-T4 was evaluated for affinity and specificity to human GIPR (huGIPR). The in vivo GIPR binding of [68Ga]S02-GIP-T4 as well as the occupancy of a drug candidate with GIPR activity were assessed in nonhuman primates (NHPs) by PET. [68Ga]S02-GIP-T4 bound with nanomolar affinity and high selectivity to huGIPR in overexpressing cells. In vivo, pancreatic binding in NHPs could be dose-dependently inhibited by coinjection of unlabeled S02-GIP-T4. Finally, subcutaneous pretreatment with a high dose of a drug candidate with GIPR activity led to a decreased pancreatic binding of [68Ga]S02-GIP-T4, corresponding to a GIPR drug occupancy of almost 90%. [68Ga]S02-GIP-T4 demonstrated a safe dosimetric profile, allowing for repeated studies in humans. In conclusion, [68Ga]S02-GIP-T4 is a novel PET biomarker for safe, noninvasive, and quantitative assessment of GIPR target distribution and drug occupancy.Keywords
This publication has 35 references indexed in Scilit:
- GIPR expression in gastric and duodenal neuroendocrine tumorsJournal of Surgical Research, 2014
- Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumorsSurgery, 2013
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and HumansScience Translational Medicine, 2013
- Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging studyThe Lancet Diabetes & Endocrinology, 2013
- In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with 68Ga-Labeled DO3A-Exendin-4Journal of Nuclear Medicine, 2013
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine TumorsJournal of Nuclear Medicine, 2013
- GIP and GLP‐1, the two incretin hormones: Similarities and differencesJournal of Diabetes Investigation, 2010
- 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Functional GIP Receptors Are Present on AdipocytesEndocrinology, 1998
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985